## **Core Concept**
The treatment of hepatitis C infection has evolved over the years, especially in pediatric populations. The goal is to achieve sustained virological response (SVR), which indicates a cure. Treatment choices depend on the genotype of the virus, the presence of cirrhosis, and previous treatment exposure.

## **Why the Correct Answer is Right**
The correct answer, , involves the use of direct-acting antivirals (DAAs), which are the preferred treatment for hepatitis C in both adults and children. Specifically, the combination of Sofosbuvir (SOF) and Ledipasvir (LDV) or other DAAs like Elbasvir/Grazoprevir or Velpatasvir/Sofosbuvir is highly effective for several genotypes. In pediatric patients, especially those 11 years old, the focus is on using these DAAs due to their high efficacy, safety profile, and shorter treatment duration compared to traditional interferon-based therapies.

## **Why Each Wrong Option is Incorrect**
- **Option A:** - This option is incorrect because Ribavirin is sometimes used in combination with DAAs for certain genotypes or in specific cases of resistance, but it is not the standalone treatment of choice for an 11-year-old with hepatitis C.
- **Option B:** - This option might refer to an outdated or less commonly used regimen, especially in pediatric patients, making it less favorable compared to DAAs.
- **Option D:** - This option could represent another less preferred or outdated treatment approach, particularly in children, due to the availability of more effective and safer DAAs.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that the treatment of hepatitis C in children has shifted towards using DAAs, which offer a higher cure rate, shorter treatment duration (usually 12-24 weeks), and better tolerability compared to older regimens. The specific DAA regimen chosen may depend on the viral genotype, the presence of liver cirrhosis, and prior treatment experience.

## **Correct Answer:** . Sofosbuvir/Ledipasvir